Literature DB >> 14604265

Ketones: metabolism's ugly duckling.

Theodore B VanItallie1, Thomas H Nufert.   

Abstract

Ketones were first discovered in the urine of diabetic patients in the mid-19th century; for almost 50 years thereafter, they were thought to be abnormal and undesirable by-products of incomplete fat oxidation. In the early 20th century, however, they were recognized as normal circulating metabolites produced by liver and readily utilized by extrahepatic tissues. In the 1920s, a drastic "hyperketogenic" diet was found remarkably effective for treatment of drug-resistant epilepsy in children. In 1967, circulating ketones were discovered to replace glucose as the brain's major fuel during the marked hyperketonemia of prolonged fasting. Until then, the adult human brain was thought to be entirely dependent upon glucose. During the 1990s, diet-induced hyperketonemia was found therapeutically effective for treatment of several rare genetic disorders involving impaired neuronal utilization of glucose or its metabolic products. Finally, growing evidence suggests that mitochondrial dysfunction and reduced bioenergetic efficiency occur in brains of patients with Parkinson's disease (PD) and Alzheimer's disease (AD). Because ketones are efficiently used by mitochondria for ATP generation and may also help protect vulnerable neurons from free radical damage, hyperketogenic diets should be evaluated for ability to benefit patients with PD, AD, and certain other neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604265     DOI: 10.1301/nr.2003.oct.327-341

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  53 in total

1.  Dynamics of starvation in humans.

Authors:  Baojun Song; Diana M Thomas
Journal:  J Math Biol       Date:  2006-09-08       Impact factor: 2.259

Review 2.  Potential for discovery of neuroprotective factors in serum and tissue from hibernating species.

Authors:  Austin P Ross; Kelly L Drew
Journal:  Mini Rev Med Chem       Date:  2006-08       Impact factor: 3.862

3.  Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Authors:  Vijay Sharma; John H McNeill
Journal:  World J Cardiol       Date:  2011-09-26

Review 4.  The ketogenic diet for the treatment of malignant glioma.

Authors:  Eric C Woolf; Adrienne C Scheck
Journal:  J Lipid Res       Date:  2014-02-06       Impact factor: 5.922

5.  Sample multiplexing with cysteine-selective approaches: cysDML and cPILOT.

Authors:  Liqing Gu; Adam R Evans; Renã A S Robinson
Journal:  J Am Soc Mass Spectrom       Date:  2015-01-15       Impact factor: 3.109

Review 6.  Ketogenic Diet: an Endocrinologist Perspective.

Authors:  Aravind Reddy Kuchkuntla; Meera Shah; Saketh Velapati; Victoria M Gershuni; Tamim Rajjo; Sanjeev Nanda; Ryan T Hurt; Manpreet S Mundi
Journal:  Curr Nutr Rep       Date:  2019-12

7.  Adaptive mechanisms regulate preferred utilization of ketones in the heart and brain of a hibernating mammal during arousal from torpor.

Authors:  Matthew T Andrews; Kevin P Russeth; Lester R Drewes; Pierre-Gilles Henry
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-03       Impact factor: 3.619

8.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

9.  (R)-3-oxobutyl 3-hydroxybutanoate (OBHB) induces hyperketonemiain Alzheimer's disease.

Authors:  Chang-Biao Chu; Li-Dong Jiao
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.